title: Thyroid hormone-induced cardiac mechano growth factor expression depends on beating activity.
abstract: The mechano growth factor (MGF), a splice variant of the IGF-I gene, was first discovered in mechanically overloaded skeletal muscle and was shown to play an important role in proliferation of muscle stem cells. Since then, the presence and effects of MGF have been demonstrated in other tissues. MGF has been shown to act neuroprotectively during brain ischemia, and pretreatment with MGF before myocardial infarction improves cardiac function. Because MGF plays a permissive role in exercise-induced skeletal muscle hypertrophy, we hypothesize that MGF is commonly involved in cardiac hypertrophy. To investigate the regulation of MGF expression in heart, mice were treated with thyroid hormone (T(3)) for 12 d to induce physiological cardiac hypertrophy. MGF mRNA expression was specifically increased in midregions of the septum and left ventricular wall. Interestingly, MGF expression strongly correlated with the increased or decreased beating frequency of hyperthyroid and hypothyroid hearts. To further investigate the mechanically dependent induction of MGF, neonatal rat cardiomyocytes were isolated and exposed to T(3). Upon T(3) treatment, cardiomyocytes increased both contractile activity measured as beats per minute and MGF as well as IGF-IEa mRNA expression. Importantly, when cardiomyocytes were contractile arrested by KCl, simultaneous exposure to T(3) prevented the up-regulation of MGF, whereas IGF-IEa was still induced. These studies demonstrated that MGF but not IGF-IEa expression is dependent on beating activity. These findings suggest that MGF is specifically stimulated by mechanical loading of the heart to mediate the hypertrophic response to thyroid hormone.
authors.affiliation: Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, P.O. Box 80.158, NL-3508 TD Utrecht, The Netherlands.
authors.forename: Miriam
authors.initials: M
authors.lastname: van Dijk-Ottens
authors.forename: Ingrid H C
authors.initials: IH
authors.lastname: Vos
authors.forename: Peter W A
authors.initials: PW
authors.lastname: Cornelissen
authors.forename: Alain
authors.initials: A
authors.lastname: de Bruin
authors.forename: Maria E
authors.initials: ME
authors.lastname: Everts
mesh_terms: D017398:Alternative Splicing; D000818:Animals; D000831:Animals, Newborn; D014644:Genetic Variation; D006980:Hyperthyroidism / Q000139:chemically induced / Q000503:physiopathology; D007037:Hypothyroidism / Q000139:chemically induced / Q000503:physiopathology; D007334:Insulin-Like Growth Factor I / Q000235:genetics* / Q000494:pharmacology / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology; D032383:Myocytes, Cardiac / Q000502:physiology; D010805:Physical Conditioning, Animal; D016133:Polymerase Chain Reaction; D011441:Propylthiouracil / Q000494:pharmacology; D012313:RNA / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D013961:Thyroid Gland / Q000502:physiology; D014284:Triiodothyronine / Q000494:pharmacology*
chemical_list: D012333:RNA, Messenger; C527564:mechano-growth factor, mouse; D014284:Triiodothyronine; D012313:RNA; D007334:Insulin-Like Growth Factor I; D011441:Propylthiouracil